Services

Our products cover almost all types of self-administration, designed to meet the needs of our pharmaceutical partners and their patients. We provide support throughout the entire process, from consultation and design, to bringing the product to market. We produce hundreds of millions of drug delivery devices each year and have achieved great success in the markets of Europe, the United States, and Asia. Our delivery times are short, cost-effective, and of superior quality.

We have a research and development team of over 50 engineers and experts, encompassing multidisciplinary scientists and engineers from fields like biology, chemistry, medicine, mechanical engineering, materials science, electronics, automation, and computer science. With a profound understanding of the self-administration device industry, we continuously delve into technological innovations, focusing on the upgrade and iteration of drug delivery device technologies.

Intellectual property is a crucial element in bringing new devices to the market. We understand that having freedom to operate (FTO) is a key part of successfully launching new products. Our design engineers work closely with both our internal and external patent experts to ensure robust intellectual property protection for all device solutions, without infringing third-party patents. Our newly launched exclusive product—the cartridge press auto-injector pen (featuring a core driving principle that is unique)—has independent intellectual property rights (with 4 invention patents and 5 new patents granted, making it the first product to break through the original patents of Novo Nordisk, with ongoing patent applications). A comprehensive patent investigation report (FTO) has been completed for the entire pen and its components.We regularly file applications to protect our device designs. Currently, we have 29 invention patents under review and 3 PCT patent applications. Additionally, we actively seek patent protection in key countries/regions. By protecting our intellectual capital, we provide our customers with the customized solutions they need to ensure significant differentiation from competitors.

Our factory is located in Suzhou, China, boasting a strong supply chain and large-scale industrial production capabilities. We are equipped with complete, fully automated production and assembly capabilities, independently developing assembly and inspection equipment, including fully automatic power component lines, fully automatic assembly lines, semi-automatic assembly lines, injection pen testers, inspection machines, and more. The company can provide customized production assembly, inspection equipment, and injection pens according to customer needs. We are also skilled in pharmaceutical-device combination submissions, offering comprehensive injection device solutions with low production costs and high quality. In 2024, we anticipate an annual production capacity of 100 million units.

We comply with all relevant international standardization guidelines, including:
 

• International Organization for Standardization ISO 13485.2016
   
• Food and Drug Administration (FDA)
   
• US DMF registration
   
• Medical Device Quality Management System Certification (TUV ISO 13485:2016)
   
• Medical Device Regulation 2017/745
   
• Medical Device Quality Management System Certification (BSI)
   
• ISO11608 Testing Protocols for Needle Based Injection Systems (NISS)

We are transitioning from IoT to an integration of AIoT/CT/IT technologies, establishing an application-level platform for AIoT & ICT. With an Industrial 4.0 philosophy, we develop comprehensive back-end production systems for biopharmaceutical companies, helping customers quickly build flat factory neural networks aligned with Industry 4.0 principles.